New CAR-T therapy targets hard-to-treat brain lymphoma in early trial
Disease control
Recruiting now
This study tests a new treatment called Anbal-cabtagene autoleucel (Anbal-cel) for people with a type of brain lymphoma (primary or secondary CNS lymphoma) that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified …
Phase: PHASE2 • Sponsor: Hyungwoo Cho • Aim: Disease control
Last updated May 07, 2026 18:41 UTC